Expression_NN
of_IN
c-fos_NN
correlates_VBZ
with_IN
IFN-alpha_NN
responsiveness_NN
in_IN
Philadelphia_NN
chromosome_NN
positive_JJ
chronic_JJ
myelogenous_JJ
leukemia_NN
._.

This_DT
study_NN
evaluates_VBZ
-LRB-_-LRB-
i_LS
-RRB-_-RRB-
constitutive_JJ
levels_NNS
of_IN
oncogene_NN
and_CC
p53_NN
transcripts_NNS
in_IN
chronic_JJ
phase_NN
CML_NN
patients_NNS
and_CC
-LRB-_-LRB-
ii_LS
-RRB-_-RRB-
their_PRP$
modulations_NNS
subsequent_JJ
to_TO
in_FW
vivo_FW
therapy_NN
with_IN
rIFN-alpha_NN
2c_NN
._.

Peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
pbmc_NN
-RRB-_-RRB-
and_CC
bone_NN
marrow_NN
cells_NNS
of_IN
26_CD
patients_NNS
were_VBD
examined_VBN
for_IN
c-fos_NN
,_,
c-myc_NN
,_,
p53_NN
and_CC
the_DT
hybrid_NN
bcr\/abl_NN
mRNA_NN
levels_NNS
._.

Results_NNS
indicated_VBD
that_IN
-LRB-_-LRB-
i_LS
-RRB-_-RRB-
constitutive_JJ
c-fos_NN
transcript_NN
levels_NNS
are_VBP
significantly_RB
higher_JJR
in_IN
patients_NNS
subsequently_RB
responding_VBG
to_TO
IFN-alpha_NN
therapy_NN
-LRB-_-LRB-
p_NN
&lt;_JJR
0.01_CD
-RRB-_-RRB-
and_CC
positively_RB
correlated_VBN
with_IN
the_DT
proportion_NN
of_IN
lymphocytes_NNS
-LRB-_-LRB-
r_NN
=_JJ
0.6895_CD
,_,
p_NN
&lt;_JJR
0.01_CD
-RRB-_-RRB-
and_CC
negatively_RB
with_IN
the_DT
proportion_NN
of_IN
immature_JJ
cells_NNS
-LRB-_-LRB-
r_NN
=_JJ
-0.568_CD
,_,
p_NN
&lt;_JJR
0.01_CD
-RRB-_-RRB-
contained_VBN
in_IN
the_DT
pbmc_NN
preparations_NNS
tested_VBN
,_,
-LRB-_-LRB-
ii_LS
-RRB-_-RRB-
constitutive_JJ
mRNA_NN
levels_NNS
of_IN
the_DT
hybrid_NN
bcr\/abl_NN
,_,
c-myc_NN
and_CC
p53_NN
are_VBP
positively_RB
correlated_VBN
with_IN
each_DT
other_JJ
,_,
but_CC
failed_VBD
to_TO
relate_VB
to_TO
disease_NN
parameters_NNS
,_,
and_CC
-LRB-_-LRB-
iii_LS
-RRB-_-RRB-
acute_JJ
and_CC
chronic_JJ
in_FW
vivo_FW
exposure_NN
to_TO
IFN-alpha_NN
is_VBZ
accompanied_VBN
by_IN
upregulation_NN
of_IN
c-fos_NN
and_CC
downregulation_NN
of_IN
c-myc_NN
mRNA_NN
levels_NNS
in_IN
responder_NN
patients_NNS
._.

